The dopaminergic stabilizers pridopidine and ordopidine enhance cortico-striatal Arc gene expression

Journal of Neural Transmission

Volumn 121, Issue 11, 2014, Pages 1337-1347

  Waters, Susanna ^a,b   Ponten, Henrik ^a   Edling, Malin ^a   Svanberg, Boel ^b   Klamer, Daniel ^a   Waters, Nicholas ^b  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b Integrative Research Laboratories   (Sweden)

Author keywords

Arc; Dopaminergic stabilizer; Dopidines; Frontal cortex; Ordopidine; Pridopidine; RT PCR; Striatum

Indexed keywords

3 (1 ADAMANTYL) 1 AMINOMETHYL 3,4 DIHYDRO 5,6 DIHYDROXY 1H 2 BENZOPYRAN; 3,4 DIHYDROXYPHENYLACETIC ACID; ACTIVITY REGULATED CYTOSKELETON ASSOCIATED PROTEIN; ARIPIPRAZOLE; DIZOCILPINE; HALOPERIDOL; MESSENGER RNA; MONOAMINE; ORDOPIDINE; PRIDOPIDINE; QUETIAPINE; QUINPIROLE; REMOXIPRIDE; RISPERIDONE; SODIUM CHLORIDE; APOPTOSIS REGULATORY PROTEIN; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; MUSCLE PROTEIN; NOL3 PROTEIN, RAT; PIPERIDINE; PIPERIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BEHAVIOR; COMPARATIVE STUDY; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFECT; FRONTAL CORTEX; GENE EXPRESSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMEDIATE EARLY GENE; IN VIVO STUDY; LOCOMOTION; MALE; NEUROCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; RAT; REAL TIME POLYMERASE CHAIN REACTION; TISSUE LEVEL; ANALYSIS OF VARIANCE; ANIMAL; BRAIN CORTEX; DRUG EFFECTS; ELECTROCHEMICAL ANALYSIS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOTOR ACTIVITY; SPRAGUE DAWLEY RAT; STATISTICS;

3,4-DIHYDROXYPHENYLACETIC ACID; ANALYSIS OF VARIANCE; ANIMALS; APOPTOSIS REGULATORY PROTEINS; CEREBRAL CORTEX; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CORPUS STRIATUM; DOPAMINE; DOPAMINE AGENTS; ELECTROCHEMICAL TECHNIQUES; GENE EXPRESSION REGULATION; MALE; MOTOR ACTIVITY; MUSCLE PROTEINS; PIPERIDINES; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; STATISTICS AS TOPIC;

EID: 84925709928     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-014-1231-1     Document Type: Article

References (47)

1. Bamford NS, Zhang H, Schmitz Y, Wu NP, Cepeda C, Levine MS, Schmauss C, Zakharenko SS, Zablow L, Sulzer D (2004) Heterosynaptic dopamine neurotransmission selects sets of corticostriatal terminals. Neuron 42:653-663
2. Bramham CR, Alme MN, Bittins M, Kuipers SD, Nair RR, Pai B, Panja D, Schubert M, Soule J, Tiron A, Wibrand K (2010) The Arc of synaptic memory. Exp Brain Res 200:125-140
3. Bruins Slot L, Lestienne F, Grevoz-Barret C, Newman-Tancredi A, Cussac D (2009) F15063, a potential antipsychotic with dopamine D(2)/D(3) receptor antagonist and 5-HT(1A) receptor agonist properties: influence on immediate-early gene expression in rat prefrontal cortex and striatum. Eur J Pharmacol 620:27-35
4. Carlsson A (1975) Dopaminergic autoreceptors. In: Almgren O, Carlsson A, Engel J (eds) Chemical tools in catecholamine research. North-Holland Publishing Company, Amsterdam, p 219
5. Carlsson A (1990) Early psychopharmacology and the rise of modern brain research. J Psychopharmacol 4:120-126
6. Carlsson A, Lindqvist M (1963) Effects on chlorpromazine or haloperidol on formation of 3-methoxy-tyramine and normetanephrine in mouse brain. Acta Pharmacol et Toxicol 20:140
7. Cepeda C, Levine MS (1998) Dopamine and N-methyl-D-aspartate receptor interactions in the neostriatum. Dev Neurosci 20:1-18
8. Cepeda C, Buchwald NA, Levine MS (1993) Neuromodulatory actions of dopamine in the neostriatum are dependent upon the excitatory amino acid receptor subtypes activated. Proc Natl Acad Sci USA 90:9576-9580
9. Cepeda C, Wu N, Andre VM, Cummings DM, Levine MS (2007) The corticostriatal pathway in Huntington's disease. Prog Neurobiol 81:253-271
10. Chen G, Greengard P, Yan Z (2004) Potentiation of NMDA receptor currents by dopamine D1 receptors in prefrontal cortex. Proc Natl Acad Sci USA 101:2596-2600
11. Chomczynski P, Sacchi N (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156-159
12. de Yebenes JG, Landwehrmeyer B, Squitieri F, Reilmann R, Rosser A, Barker RA, Saft C, Magnet MK, Sword A, Rembratt Å, Tedroff J, On Behalf of the MermaiHD Study Investigators (2011) The dopaminergic stabilizer pridopidine improves motor function in patients with Huntington's disease: results from a phase 3, randomized, placebo-controlled study (MermaiHD). Lancet Neurol 10:1049-1057
13. Dyhring T, Nielsen EØ, Sonesson C, Pettersson F, Karlsson J, Svensson P, Christophersen P, Waters N (2010) The dopaminergic stabilizers pridopidine (ACR16) and (-)-OSU6162 display dopamine D(2) receptor antagonism and fast receptor dissociation properties. Eur J Pharmacol 628:19-26
14. El-Sayeh HG, Morganti C (2006) Aripiprazole for schizophrenia. Cochrane Database Syst Rev 2:CD004578
15. Fiorentini C, Busi C, Spano P, Missale C (2010) Dimerization of dopamine D1 and D3 receptors in the regulation of striatal function. Curr Opin Pharmacol 10(1):87-92
16. Flores-Herná'ndez J, Cepeda C, Herná'ndez-Echeagaray E, Calvert CR, Jokel ES, Fienberg AA, Greengard P, Levine MS (2002) Dopamine enhancement of NMDA currents in dissociated medium-sized striatal neurons: role of D1 receptors and DARPP- 32. J Neurophysiol 88:3010-3020
17. Fumagalli F, Frasca A, Racagni G, Riva MA (2009) Antipsychotic drugs modulate Arc expression in the rat brain. Eur Neuropsychopharmacol 19:109-115
18. Gao K, Ganocy SJ, Gajwani P, Muzina DJ, Kemp DE, Calabrese JR (2008) A review of sensitivity and tolerability of antipsychotics in patients with bipolar disorder or schizophrenia: focus on somnolence. J Clin Psychiatry 69:302-309
19. Gonzalez-Islas C, Hablitz JJ (2003) Dopamine enhances EPSCs in layer II-III pyramidal neurons in rat prefrontal cortex. J Neurosci 23:867-875
20. Gronier B, Waters S, Ponten H (2013) The dopaminergic stabilizer pridopidine increases neuronal activity of presumed pyramidal neurons in the prefrontal cortex. J Neural Transm 120(9):1281-1294
21. Kamińska K, Gołembiowska K, Rogóż Z (2013) Effect of risperidone on the fluoxetine-induced changes in extracellular dopamine, serotonin and noradrenaline in the rat frontal cortex. Pharmacol Rep 65(5):1144-1151
22. Kawashima T, Okuno H, Nonaka M, Adachi-Morishima A, Kyo N, Okamura M, Takemoto-Kimura S, Worley PF, Bito H (2009) Synaptic activity-responsive element in the Arc/Arg3.1 promoter essential for synapse-to-nucleus signalling in activated neurons. Proc Natl Acad Sci USA 106:316-321
23. Korb E, Finkbeiner S (2011) Arc in synaptic plasticity: from gene to behaviour. Trends Neurosci 34(11):591-598
24. Link W, Konietzko U, Kauselmann G, Krug M, Schwanke B, Frey U, Kuhl D (1995) Somatodendritic expression of an immediate early gene is regulated by synaptic activity. Proc Natl Acad Sci USA 92:5734-5738
25. Lyford GL, Yamagata K, Kaufmann WE, Barnes CA, Sanders LK, Copeland NG, Gilbert DJ, Jenkins NA, Lanahan AA, Worley PF (1995) Arc, a growth factor and activity-regulated gene, encodes a novel cytoskeleton-associated protein that is enriched in neuronal dendrites. Neuron 14:433-445
26. Maggio R, Millan MJ (2010) Dopamine D2-D3 receptor heteromers: pharmacological properties and therapeutic significance. Curr Opin Pharmacol 10(1):100-107
27. Nakahara T, Kuroki T, Hashimoto K, Hondo H, Tsutsumi T, Motomura K, Ueki H, Hirano M, Uchimura H (2000) Effect of atypical antipsychotics on phencyclidine-induced expression of Arc in rat brain. NeuroReport 11:551-555
28. Natesan S, Svensson KA, Reckless GE, Nobrega JN, Barlow KB, Johansson AM, Kapur S (2006) The dopamine stabilizers (S)-(-)-(3-methanesulfonyl-phenyl)-1-propyl-piperidine [(-)- OSU6162] and 4-(3-methanesulfonylphenyl)-1-propyl-piperidine (ACR16) show high in vivo D2 receptor occupancy, antipsychotic-like efficacy, and low potential for motor side effects in the rat. J Pharmacol Exp Ther 318:810-818
29. Pei Q, Tordera R, Sprakes M, Sharp T (2004) Glutamate receptor activation is involved in 5-HT2 agonist-induced Arc gene expression in the rat cortex. Neuropharmacology 46:331-339
30. Pettersson F, Pontén H, Waters N, Waters S, Sonesson C (2010) Synthesis and evaluation of a set of 4-phenylpiperidines and 4-phenylpiperazines as D2 receptor ligands and the discovery of the dopaminergic stabilizer 4-[3-(methylsulfonyl)phenyl]-1-propylpiperidine (huntexil, pridopidine, ACR16). J Med Chem 53:2510-2520
31. Ponten H, Dyhring T, Edling M, Pettersson F, Sonesson C, Svanberg B, Swanson L, Tedroff J, Waters S, Waters N (2009) ACR325: a dopaminergic stabiliser that displays state-dependent effects in vivo. Eur Neuropsychopharmacol 19(Suppl 3):S276
32. Ponten H, Kullingsjö J, Lagerkvist S, Martin P, Pettersson F, Sonesson C, Waters S, Waters N (2010) In vivo pharmacology of the dopaminergic stabilizer pridopidine. Eur J Pharmacol 644:88-95
33. Robbins MJ, Critchlow HM, Lloyd A, Cilia J, Clarke JD, Bond B, Jones DN, Maycox PR (2008) Differential expression of IEG mRNA in rat brain following acute treatment with clozapine or haloperidol: a semi-quantitative RT-PCR study. J. Psychopharmacol. 22:536-542
34. Seamans JK, Durstewitz D, Christie BR, Stevens CF, Sejnowski TJ (2001) Dopamine D1/D5 receptor modulation of excitatory synaptic inputs to layer V prefrontal cortex neurons. Proc Natl Acad Sci USA 98:301-306
35. Serres F, Rodriguez M, Rivet J-M, Galizzi J-P, Lockhart B, Sharp T, Millan MJ (2012) Blockade of î ± 2-adrenoceptors induces Arc gene expression in rat brain in a glutamate receptor-dependent manner: a combined qPCR, in situ hybridisation and immunocytochemistry study. Neuropharmacology 63:992-1001
36. Silverstone PH, Lalies MD, Hudson AL (2012) Quetiapine and buspirone both elevate cortical levels of noradrenaline and dopamine in vivo, but do not have synergistic effects. Front Psychiatry 3:82. doi:10.3389/fpsyt.2012.00082
37. Sonesson C, Swanson L, Waters N (2005) New disubstituted phenylpiperidines/piperazines as modulators of dopamine neurotransmission. World Intellectual Property Organization patent WO 2005/121087
38. Sonesson C, Andersson B, Waters S, Waters N, Tedroff J (2001) New modulators of dopamine neurotransmission. World Intellectual Property Organization patent WO 2001/46145
39. Stahl SM (2001) Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 1, "Goldilocks" actions at dopamine receptors. J Clin Psychiatry 62:841-842
40. Steward O, Worley PF (2001) Selective targeting of newly synthesized Arc mRNA to active synapses requires NMDA receptor activation. Neuron 30:227-240
41. Surmeier DJ, Ding J, Day M, Wang Z, Shen W (2007) D1 and D2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons. Trends Neurosci 30:228-235
42. The Huntington Study Group HART Investigators (2013) A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington's disease. Mov Disord. doi:10.1002/mds.25362
43. Tseng KY, O'Donnell P (2004) Dopamine-glutamate interactions controlling prefrontal cortical pyramidal cell excitability involve multiple signaling mechanisms. J Neurosci 24:5131-5139
44. Wang J, O'Donnell P (2001) D1 dopamine receptors potentiate NMDA-mediated excitability increase in layer V prefrontal cortical pyramidal neurons. Cereb Cortex 11:452-462
45. Waters S, Martin P, Pettersson F, Ponten H, Sonesson C, Swanson L, Waters N (2006) Pharmacology of the dopaminergic stabilizer and glutamate enhancer ACR325 Society for Neuroscience Annual Conference, Atlanta, USA. Abstract Viewer/Itinerary Planner: Program No. 828.18
46. Yamagata K, Suzuki K, Sugiura H, Kawashima N, Okuyama S (2000) Activation of an effector immediate-early gene Arc by methamphetamine. Ann N Y Acad Sci 914:22-32
47. Yin HH, Lovinger DM (2006) Frequency-specific and D2 receptormediated inhibition of glutamate release by retrograde endocannabinoid signaling. Proc Natl Acad Sci USA 103:8251-8256